Selective PI-PLC inhibitor, also PAF receptor agonist
ET 18-OCH3 is a synthetic lysophospholipid analog that selectively inhibits phosphatidylinositol phospholipase C (IC50 = 9.6 μM in fibroblasts and adenocarcinoma cells). ET 18-OCH3 acts as an agonist at platelet-activating factor (PAF) receptors. ET 18-OCH3 is an antitumor lipid that selectively induces apoptosis in tumor cells, sparing normal cells, and activates the intracellular Fas/CD95 death receptor. ETH 18-OCH3 also triggers eryptosis and interacts with mitochondrial membranes to increase mitochondrial membrane permeability, leading to dysfunction and apoptosis. Racemic mixture.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-125323 |
| Réf. fabricant | 18074992 |
| Nom chimique ou matériau | 4-Hydroxy-7-methoxy-N,N,N-trimethyl-3,5,9-trioxa-4-phosphaheptacosan-1-aminium 4-oxide |
| CAS | 70641-51-9 |
| Quantité | 10 mg |
| Cible | Phospholipase C Inhibitors |
| Formule moléculaire | C<sub>27</sub>H<sub>58</sub>NO<sub>6</sub>P |
